Share

April 2015; 5 (2) Clinical and Ethical Challenges

Multiple sclerosis in US minority populations

Clinical practice insights

Omar Khan, Mitzi J. Williams, Lilyana Amezcua, Adil Javed, Kristin E. Larsen, Jennifer M. Smrtka
First published January 16, 2015, DOI: https://doi.org/10.1212/CPJ.0000000000000112
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2151

Share

Article Information

vol. 5 no. 2 132-142
DOI: 
https://doi.org/10.1212/CPJ.0000000000000112
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published January 16, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Omar Khan, MD,
    2. Mitzi J. Williams, MD,
    3. Lilyana Amezcua, MD,
    4. Adil Javed, MD, PhD,
    5. Kristin E. Larsen, PhD and
    6. Jennifer M. Smrtka, NP
  1. Omar Khan, MD,
    2. Scientific Advisory Boards:

    1. Teva Pharmaceuticals, Biogen Idec, National MS Society, Genentech/Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Teva Pharmaceuticals, Novartis, Biogen Idec

    Editorial Boards:

    1. Journal of Neurological Sciences, member Editorial Board.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Teva Pharmaceuticals, Novartis, Biogen Idec, EMD Serono, Roche, Genzyme, Questcor

    Speakers' Bureaus:

    1. Teva Pharmaceuticals, Novartis, Biogen Idec

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Teva Pharmaceuticals, Novartis, Biogen Idec, Genzyme, Roche

    Research Support, Government Entities:

    1. NIH

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, DMC Foundation, Sastry Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Mitzi J. Williams, MD,
    3. Scientific Advisory Boards:

    1. 1. Biogen Idec 2. TEVA Neuroscience 3. Bayer 4. Questcor Pharmaceuticals, 5. EMD Serono 6. Pfizer 7. Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Biogen Idec - speaker bureau, travel to speaker training and consultant meetings 2. TEVA Neuroscience - speaker bureau, travel to speaker training and consultant meetings 3. Bayer - speaker bureau, travel to speaker training and consultant meetings, Sales meeting professional panel 5. Questcor Pharmaceuticals - speaker bureau, travel to speaker training and consultant meetings 6. EMD Serono -speaker bureau, travel to speaker training and consultant meetings, 7. Pfizer - speaker bureau, 8. Novartis - speaker bureau, travel to speaker training and consultant meetings, Medical science liason training 9. Accorda- travel to speaker training

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Biogen Idec 2. TEVA Neuroscience 3. Bayer 4. Questcor Pharmaceuticals, 5. Novartis 6. EMD Serono

    Speakers' Bureaus:

    1. 1. Biogen Idec 2. TEVA Neuroscience 3. Bayer 4. Questcor Pharmaceuticals, 5. EMD Serono 6. Pfizer 7. Novartis 8. Accorda 9. Genzyme

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Lilyana Amezcua, MD,
    4. Scientific Advisory Boards:

    1. 1) Biogen Idec 2) Novartis 3) Acorda

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Biogen 2) Novartis 3) Genzyme 4) Acorda

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Biogen 2) Novartis 3) Genzyme 4) Acorda 5) TEVA

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Adil Javed, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have been a consultant for Bayer, Biogen, Questcor, Novartis, and Teva Neuroscience.

    Speakers' Bureaus:

    1. I have been a consultant for Bayer, Biogen, Questcor, Novartis, and Teva Neuroscience.

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Kristin E. Larsen, PhD and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. a professional medical writer employed by ProEd Communications, Inc. at the time of manuscript development. Biogen Idec provided funding to ProEd Communications, Inc. for editorial support in the development of this paper.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Jennifer M. Smrtka, NP
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Acorda- speaker honoraria (2) Bayer- speaker honoraria (3) Biogen- travel and speaker honoraria (4)Genzyme- speaker honoraria (5) Novartis- travel and speaker honoraria (6) Pfizer- speaker honoraria (7) Teva- travel and speaker honoraria (8) Questcor-travel and speaker honoraria

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Multiple Sclerosis of America (2) National Multiple Sclerosis Society (3) CAN DO MS (4) Acorda (5) Questcor

    Speakers' Bureaus:

    1. (1) Acorda(2) Bayer (3) Biogen (4)Genzyme (5) Novartis (6) Pfizer (7) Teva (8) Questcor

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (OK), Wayne State University School of Medicine, Detroit, MI; Multiple Sclerosis Center of Atlanta (MJW), GA; Department of Neurology (LA), Keck School of Medicine, University of Southern California, Los Angeles; Department of Neurology (AJ), University of Chicago School of Medicine, IL; ProEd Communications (KEL), Beachwood, OH; and South Florida Neurology Associates (JMS), Boca Raton.
  1. Correspondence to:
    okhan{at}med.wayne.edu
View Full Text

Article usage

Article usage: January 2015 to August 2021

AbstractFullPdfSource
Jan 2015311010Highwire
Feb 2015167013Highwire
Mar 20159404Highwire
Apr 2015748930Highwire
May 20157285448Highwire
Jun 2015227110Highwire
Jul 201511117Highwire
Aug 20157601Highwire
Sep 201573010Highwire
Oct 20157833Highwire
Nov 201510706Highwire
Dec 201515402Highwire
Jan 201611211Highwire
Feb 20168211Highwire
Mar 201612113Highwire
Apr 20167900Highwire
Apr 20160227pmc
May 20166501Highwire
May 201602010pmc
Jun 20167702Highwire
Jun 20160147pmc
Jul 201612400Highwire
Jul 20160296pmc
Aug 20169400Highwire
Aug 20160298pmc
Sep 201615200Highwire
Sep 201605823pmc
Oct 20169102Highwire
Oct 201606811pmc
Nov 20165000Highwire
Nov 201608118pmc
Dec 20163800Highwire
Dec 20160606pmc
Jan 20175430Highwire
Jan 201709914pmc
Feb 20173101Highwire
Feb 2017015823pmc
Mar 20174003Highwire
Mar 2017016019pmc
Apr 20173001Highwire
Apr 201718145157pmc
May 20173710Highwire
May 201713105140pmc
Jun 20172401Highwire
Jun 201718116155pmc
Jul 20171402Highwire
Jul 2017896110pmc
Aug 20173500Highwire
Aug 201710140170pmc
Sep 20171600Highwire
Sep 201716115148pmc
Oct 20174402Highwire
Oct 201721130175pmc
Nov 20172900Highwire
Nov 201713156204pmc
Dec 20173651Highwire
Jan 201812400Highwire
Feb 20183810Highwire
Mar 20182410Highwire
Apr 20183220Highwire
Apr 201813169202pmc
May 20184000Highwire
Jun 20182300Highwire
Jun 20186117137pmc
Jul 20183203Highwire
Aug 20182100Highwire
Aug 20189120130pmc
Sep 20184011Highwire
Oct 20182101Highwire
Nov 20181540Highwire
Dec 20182600Highwire
Jan 20195820Highwire
Feb 20194200Highwire
Mar 20196652Highwire
Apr 20193716Highwire
May 20195814Highwire
Jun 20194232Highwire
Jul 20193212Highwire
Aug 20193902Highwire
Sep 20193131Highwire
Oct 20192622Highwire
Nov 20194674Highwire
Dec 20194521Highwire
Jan 20203821Highwire
Feb 20203862Highwire
Mar 20203242Highwire
Apr 20205114Highwire
May 20204022Highwire
Jun 20202803Highwire
Jul 20204901Highwire
Aug 20204934Highwire
Sep 20208245Highwire
Oct 20207456Highwire
Nov 20208822Highwire
Dec 20204385Highwire
Jan 2021771114Highwire
Feb 20218184Highwire
Mar 20218153Highwire
Apr 20216398Highwire
May 202160152Highwire
Jun 202139103Highwire
Jul 20216112Highwire
Aug 2021210102Highwire

The Nerve!: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me